Second Malignancies in TKI treated Chronic Myeloid Leukemia

PANKAJ MALHOTRA, MDChandigarh, India

• Associate Professor, Department of Internal Medicine Pgimer, Chandigarh, India

• Dr. Pankaj Malhotra received his medical degree from Punjab University and his training in internal medicine at PGIMER, Chandigarh, India. He has several invited and peer reviewed publications. Dr. Malhotra was awarded the CML Fellowship by International CML Foundation (iCMLF) to Knight Cancer Centre, Oregon Science and Health University, Portland, USA. Areas of Interest include leukemia, stem cell transplant and myeloma.

Second Malignancies in TKI treated CML

Pankaj Malhotra, MD, FACP

Professor of Clinical Hematology

Dept. of Internal Medicine, PGIMER, Chandigarh, India

Components of my talk

• Reasons for discussing this topic

• Case reports

• Case series

• Systemic studies

• SEER database analysis

• Conclusions

Why are we discussing this topic?

• CML: Survival almost equivalent to normal population

• Life long therapy

• Other actions of TKI• T cells

• Immunomodulatory effect

• Immunosuppressive effect

Components of my talk

• Reasons for discussing this topic

• Case reports

• Case series

• Systemic studies

• SEER database analysis

• Conclusions

Components of my talk

• Reasons for discussing this topic

• Case reports

• Case series

• Systemic studies

• SEER database analysis

• Conclusions

Components of my talk

• Reasons for discussing this topic

• Case reports

• Case series

• Systemic studies

• SEER database analysis

• Conclusions

Conclusions

• Available literature suggests mild increased risk of SPM in patients with CML

• Increased prevalence of SPM in TKI era appears to be due to increased longevity of CML patients

• No clear data to implicate TKI as risk factor for SPM

• CML patients continue to follow good life style measures (avoid smoking, regular exercise etc..)